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The study of human genetics has recently 
undergone a dramatic transition with the com-
pletion of both the sequencing of the human 
genome and the mapping of human haplo-
types of the most common form of genetic 
variation, the single nucleotide polymorphism 
(SNP)1–3. In concert with this rapid expansion 
of detailed genomic information, cost-effective 
genotyping technologies have been developed 
that can assay hundreds of thousands of SNPs 
simultaneously. Together, these advances have 
allowed a systematic, even ‘agnostic’, approach 
to genome-wide interrogation, thereby relaxing 
the requirement for strong prior hypotheses. 
So far, comprehensive reviews of the pub-
lished literature, most of which reports work 
based on the candidate-gene approach, have 
demonstrated a plethora of questionable geno-
type–phenotype associations, replication of 
which has often failed in independent stud-
ies4–7. As the transition to genome-wide asso-
ciation studies occurs, the challenge will be to 
separate true associations from the blizzard of 
false positives attained through attempts to rep-
licate positive findings in subsequent studies. 
The purpose of a replication study is to evalu-
ate a positive finding from a previous study, 
to provide credibility that the initial finding is 
valid. Replication is essential for establishing 
the credibility of a genotype–phenotype asso-
ciation, whether derived from candidate-gene 
or genome-wide association studies. However, 
there is a lack of agreement about what consti-
tutes a finding deserving of replication, what 
constitutes an adequate replication study and 
what constitutes a replication or refutation.
Investigators and journal editors have offered 
guidelines for how to address this problem8–12, 
but these initial efforts have been hampered by 
limited experience and conflicting empirical 
data. However, as evidence has accumulated, 
several instructive examples have emerged 
of genotype–phenotype associations being 
reproduced reliably in follow-up studies. These 
include peroxisome proliferator-activated 
receptor-γ (PPARG)13 and the transcription 
factor TCF7L2 (refs 14–19), related to diabetes; 
nucleotide-binding oligomerization domain 
containing 2 (NOD2) and Crohn’s disease20–22; 
complement factor H (CFH) and age-related 
macular degeneration23–26; and chromosome 
region 8q24 and prostate cancer risk27–31. 
Many instances have arisen in which initial 
findings have not been reproduced in follow-up 
studies because of issues in either the initial 
study or the attempted replication4–6,32,33. Small 
sample size is a frequent problem and can result 
in insufficient power to detect minor contri-
butions of one or more alleles. Similarly, small 
sample sizes can provide imprecise or incor-
rect estimates of the magnitude of the observed 
effects. Poor study design — particularly a lack 
of comparability between cases and controls 
— can increase the risk of biases because there 
can be heterogeneity in exposure to environ-
mental challenges and population stratifica-
tion. The latter arises when investigators fail 
to account for case–control differences in the 
genetic structure of the underlying population. 
Heterogeneity in classification of outcomes 
across studies can undermine the opportu-
nity to compare among them. Similarly, data 
‘dredging’ can be a major problem, especially 
when criteria for defining phenotypes are 
altered to achieve statistical significance worthy 
of publication. 
Another challenge arises when follow-up 
studies analyse different variants. An example 
is the reported association between DTNBP1 
and schizophrenia, initially identified in Irish 
pedigrees34 and ‘confirmed’ in independent 
European studies35. Unfortunately, different 
risk alleles and haplotypes were reported in 
each study, making comparison difficult36–39. 
Although it is plausible that more than one 
variant could contribute to schizophrenia risk 
at the DTNBP1 locus, it is difficult to draw this 
conclusion from the literature because follow-
up studies have not consistently analysed the 
same markers or those in perfect linkage dis-
equilibrium (r2 = 1.0). Other recent examples 
for which initial reports of association have 
been inconsistently replicated include insu-
lin-induced gene 2 (INSIG2) and obesity40–44, 
and cyclic-AMP-specific phosphodiesterase 
(PDE4D) and stroke45,46. These have been 
accompanied by controversies about what 
actually constitutes replication. 
This paper presents the conclusions of a 
working group on the replication of geno-
type–phenotype associations — whether 
identified in genome-wide or candidate-gene 
studies — convened by the National Cancer 
Institute and the National Human Genome 
Research Institute. The group was composed 
of experts from diverse disciplines, including 
biostatistics, clinical medicine, epidemiology, 
genetics and scientific publishing. The purpose 
was to review the current state of the field and 
propose best practices for the design, conduct 
and publication of replication studies that aim 
to follow up notable findings, particularly in 
genome-wide association studies. The group 
addressed three topics. First, assessment of the 
validity and limitations of any single genetic 
association study. Second, criteria for establish-
ing replication in genetic association studies. 
Third, points to consider for publication of 
high-quality genotype–phenotype association 
reports (Box 1). 
Replicating genotype–phenotype associations
What constitutes replication of a genotype–phenotype association, and how best can it be achieved? 
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The initial study of any association represents 
an important discovery tool. In the near future, 
it is unlikely that a single study will unequivo-
cally establish a valid genotype–phenotype 
association and not require replication. A 
number of points relating to the study design 
and reporting should be considered in deter-
mining whether a finding in an initial genome-
wide or candidate-gene study merits follow-up 
replication studies (Box 2). Attempts to repli-
cate a reported association are often compli-
cated by lack of methodological detail in the 
initial report or lack of methodological rigour 
in the original study.
Because of the enormous number of geno-
type–phenotype associations tested in each 
genome-wide study, spurious associations will 
substantially outnumber true ones unless rigor-
ous statistical thresholds are applied. Although 
no universal threshold can be specified for 
statistical significance in all circumstances, 
smaller P-values generally provide greater sup-
port for a true association. Extremely small P-
values should be interpreted carefully, however, 
until completion of replication studies, because 
many can be due to inappropriate reliance on 
asymptotic distributions of test statistics, or 
to technical artefact or genotype errors that 
are distributed differently between cases and 
controls. Cluster plots for highly significant 
markers should be examined carefully. It may 
be desirable to include confirmatory data from 
a second genotyping technology in the initial 
report to verify genotype accuracy. Cases and 
controls should be drawn from populations 
that are generally comparable both in terms 
of genetic background and environmen-
tal exposures47, and should be analysed for 
This checklist is intended to serve as a guide for 
authors, journal editors and referees to allow 
clear and unambiguous interpretation of the 
data and results of genome-wide and other 
genotype–phenotype association studies. 
Study information 
• A detailed description of the study design and 
its implementation
• The source of cases and controls (or cohort 
members, if based on cohort design), 
including time period and location(s) of 
subject recruitment 
• Methods for ascertaining and validating 
affected or unaffected status and 
reproducibility of classification
• Participation rates for cases, controls or 
cohort members
• Presentation of case and control selection 
in a flow chart, including exclusion points 
for missing and erroneous data (possibly as 
supplementary tables)
• Initial table comparing relevant 
characteristics (such as demographics, risk 
factors and exposures) of cases and controls
• Success rate for DNA acquisition, including 
comparisons of those with and without 
collection, extraction failures and exclusions 
due to inconsistent data 
Data issues
• Statement on availability of results and data 
so that, as far as possible, others can analyse 
them independently
• Links to supplemental online resources and 
database accession numbers
Genotyping and quality control procedures  
• Sample tracking methods, such as bar-
coding, to ensure accuracy of analysis 
• Description of genotyping assays and 
protocols, particularly when new or applied in 
a non-standard method
• Description of genotyping calling algorithm 
• Genotype quality control design for samples, 
including numbers, plating locations, 
selection criteria for:
 • External control samples from standard 
accepted sets (such as HapMap)
 • Internal control samples (duplicate 
samples; it should be specified whether 
these are from the same or different DNA 
collection, extraction or aliquot)
• Assay and DNA quality metrics by locus, 
sample, plate or ‘batch’
• Assay call rates
• Average error rates estimated by internal 
duplicates or external samples 
• Assay reproducibility: concordance for 
performance of extraction, aliquoting 
(internal control samples) and assay 
reproducibility
• Concordance with published or previously 
generated genotypes
• Mendelian consistency checks if related 
individuals are present
• Detection of inconsistent or cryptic 
relatedness in study subjects
• Evaluation of deviations from Hardy–
Weinberg proportions to detect failed assays 
or large-scale stratification (for example, 
testing Hardy–Weinberg equilibrium 
‘violations’) separately in cases and controls
• Assessment of population heterogeneity, 
including
 • Average or median value of chi-square and 
full distribution
 • Q–Q plots of chi-square analysis and P-
values (with specific description of type of 
test used to generate the values)
• Validation of most critical results on an 
independent genotyping platform
Results
• Analysis methods in sufficient detail to 
reconstruct the analytical approach and 
reproduce all reported results
• Description of any pre-analysis weighting 
scheme for selecting variants for replication
• Simple single-locus and multi-marker 
(haplotype) association analyses
• Genetic models tested (unconstrained 
genotype effects — dominant, additiv e, 
multiplicative or trend)
• Graphical display of genotype clustering for 
assays of high interest 
• Verification of results at highly correlated loci
• Discussion of choice of threshold for 
significance and the statistical basis for 
any adjustment for multiple testing and the 
relationship to overall study power
• Significance of any known ‘positive controls’ 
(that is, loci established in previous genetic 
associations)
• Consistency of results before and after 
application of quality control filters
Replication studies
• Description of replication samples, including 
source, ascertainment and comparability to 
initial sample
• Discussion of choice of threshold for 
significance and the statistical basis for 
any adjustment for multiple testing and the 
relationship to overall study power
• Summary of replication and analysis attempts 
by authors
• Summary of all known replication attempts 
by others, including non-replications
Genotyping data and specifications for 
deposition in standard databases 
• Availability of ‘raw’ genotype data in the 
technology and vendor format, consistent 
with the requirements or restrictions 
imposed by funding agencies or informed 
consent
• Data extraction and processing 
protocols
• Normalization, transformation and data 
selection procedures and parameters
Points for reviewers and authors to consider 
regarding priority for publication
• Strength of observation
• Suitably large sample size
• Sufficiently stringent criteria for significance 
(small P-values)
• High quality of study design, including 
selection of study population, reliability of 
phenotypes, measurement and adjustment 
for potential confounders
• Discussion and conclusions commensurate 
with sample size, power, P-value and 
epidemiological quality of study design
• Quality control standards used, including 
assessment of genotype quality and 
completeness
• Usefulness of observations to others for 
subsequent research
• Value of initial hypothesis described
• Brief presentation of implications, especially 
as they relate to further follow-up both of 
genetic markers and for corroborative studies 
to investigate plausibility
• Explanations of notable findings
• Appropriate alternative explanations 
proposed and briefly discussed
• Biological or functional explanations based 
firmly on available data
Box 1 | Points to consider in genotype–phenotype association reports
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confounding population stratification. This 
may require genotyping of ancestry informa-
tive markers (AIMs), which should be strongly 
encouraged as genotype costs fall and AIMs 
become increasingly well-characterized within 
marker sets. Family-based studies are affected 
by population stratification, so researchers 
should opt for methods robust to this, such as 
transmission disequilibrium methods48. They 
may be particularly valuable in the initial study 
if there is evidence for ethnic differences in the 
genetic effect of a trait, although at the cost of 
increased genotyping. Cautious interpretation 
is required either if significance is observed 
only for unusual or highly specific phenotypes 
(especially if they represent a small proportion 
of the study sample) or if significance depends 
on a particular analytical method that is not 
publicly available for confirmation. 
Approaches for dealing with multiple com-
parisons are beyond the scope of this report, 
but more robust methods are clearly needed49. 
Permutation testing is an effective strategy to 
address the problem of multiple comparisons, 
especially if a large number of phenotypes are 
being analysed. Many methods for addressing 
the problem of multiple comparisons invoke 
a conservative approach, namely a standard 
Bonferroni correction, which assumes the inde-
pendence of all tests performed. In many asso-
ciation studies, markers are not independent 
because they are in linkage disequilibrium, and 
so a standard Bonferroni correction is overly 
conservative. Lowering the threshold for call-
ing a finding of particular variants — such as 
non-synonymous coding SNPs — positive in 
the analysis scheme (weighting) has merit but 
must be declared before initiation of the analy-
sis and not once the analysis has begun49,50. The 
number of variants for which there is either 
credible laboratory evidence or a validated in 
silico prediction a priori is quite small. However, 
the temptation to create a credible biological 
hypothesis post hoc can be quite strong.
At present, many studies are barely powered 
to identify, much less to establish, associations 
of common alleles of weak effect in complex 
diseases51,52. Recently, appreciation of this 
crucial issue has led to larger, more definitive 
studies, such as the Cancer Genetic Markers 
of Susceptibility (CGEMS) project and the 
Wellcome Trust Case Control Consortium, 
(WTCCC). An estimated large effect (that is, 
with an odds ratio greater than 2) in a well-
powered study can lend credence to an associa-
tion, because unknown confounding factors 
are less likely to produce large effects53. Unfor-
tunately, many risk variants contribute less than 
this. Small studies are prone to large variation 
in risk estimates, of which only selected strong 
positives are initially detected and reported. 
Furthermore, the estimate of the effect declines 
as replication studies are pursued, a phenom-
enon known as ‘winner’s curse’54,55.
Consortial studies comprised of multiple 
independent studies combined into a pooled 
analysis can be viewed as a practical approach 
that overcomes many of the disadvantages of 
a disconnected set of underpowered studies. 
In addition, consortia may meet the need for 
rapid replication by achieving sufficiently large 
sample size40,56. Collaborations among multi-
ple independent studies can offer important 
advantages over a single large study, particu-
larly regarding the generalizability of findings 
observed in multiple studies that typically have 
greater diversity of populations and/or expo-
sures. 
As far as possible, similarly rigorous cri-
teria should be considered for evaluation 
of genotype–phenotype association studies 
with limited or no availability of subjects for 
replication, such as studies of rare diseases or 
severe toxicity due to therapy or environmen-
tal exposures. In these circumstances, addi-
tional information gathered from laboratory 
techniques, bioinformatic tools and a priori 
biological insight should be used to provide 
plausibility for interpreting genetic association 
findings. The expectation for demonstrated 
replication might be relaxed if it is unethical to 
attempt replication — such as in studies that 
link genetic variation with adverse effects of 
therapy or environmental exposure (for exam-
ple, benzene or cigarette smoke). Similarly, the 
public health impact of a finding may lessen 
the stringency of expectation for replication 
before initial publication — for example, in an 
urgent situation in which effective intervention 
is available and can be readily implemented.
Genotype–phenotype associations that have 
been replicated widely have often used clearly 
defined phenotypes classified by standard and 
widely-accepted criteria, such as diabetes and 
age-related macular degeneration57,58. Use of 
accepted criteria should reduce misclassification 
rates59. Some association studies have reported 
intermediate phenotypes (known as endophe-
notypes) but have provided little detail on the 
actual measure or its reliability60. In the absence 
of standard criteria, sufficient detail should 
be provided for both the definition of the pheno-
types investigated and assessment of their 
validity and comparability across studies.
Replication of initial studies
To establish a positive replication of a geno-
type–phenotype association, many of the same 
considerations important for genome-wide 
association or candidate-gene studies should 
be fulfilled (Box 3). In replication studies, 
every effort should be made to analyse phe-
notypes comparable to those reported in the 
initial study. In the first attempt to replicate 
a finding, comparable populations should 
be analysed not only for the main effect but 
also to guard against confounding population 
stratification, either in the initial or replica-
tion studies61,62. Because many initial studies 
and replication studies have been reported in 
populations of European descent, the challenge 
remains to extend the studies to other popu-
lations. It has already been shown that many 
variants that have a significant association with 
disease in several studies in one population 
may not necessarily have the same association 
in another (such as TCF7L2 in West Africa and 
These criteria are intended for studies of 
genotype–phenotype associations assessed by 
genome-wide or candidate-gene approaches. 
• Statistical analyses demonstrating the level 
of statistical significance of a finding should 
be published or at least available so that 
others can attempt to reproduce the reported 
results
• Explicit information should be provided 
about the study’s power to detect a range of 
effects 
• The study should be epidemiologically 
sound, with careful accounting for 
potential biases in selection of subjects, 
characterization of phenotypes, 
comparability of environmental exposures 
(when possible) and underlying population 
structure in cases and controls
• Phenotypes should be assessed according to 
standard definitions provided in the report 
• Associations should be consistent (within 
the range of expected statistical fluctuation) 
and reported for the same phenotypes 
across study subgroups or across similar 
phenotypes in the entire study group 
• Significance should not depend on altering 
the quality control methods beyond standard 
approaches that could change inclusion or 
exclusion of large numbers of samples or loci
• Measures to assess the quality of genotype 
data should include results of known study 
sample duplicates or publicly available 
samples
• The results for concordance between 
duplicate samples (if applicable) as well as 
completion and call rates per SNP and per 
subject should be disclosed, along with rates 
of missing data 
• A subset of notable SNPs should be evaluated 
with a second technology that verifies the 
same result with excellent concordance, 
because no technology is error-free 
• Associations with nearby SNPs in strong 
linkage disequilibrium with the putatively 
associated SNP should be reported (and 
should be similar) 
• The results of replication studies of previous 
findings should be reported even if the results 
are not significant
• Testing for differences in underlying 
population structure in case and control 
groups should be performed and reported
• Appropriate correction for multiple 
comparisons across all statistical tests 
examined should be reported. Comparison 
to genome-wide thresholds should 
be described. Similarly, for bayesian 
approaches, the choice of prior probabilities 
should be described
Box 2 | Suggested criteria for establishing the soundness of an initial association report
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East Asia18,63,64; in this case, it has provided an 
opportunity to refine the signal to a restricted 
region). In some circumstances, it might be 
impossible to conduct follow-up studies 
because of the uniqueness of a study popu-
lation or the lack of availability of additional 
subjects for replication. If replication is not an 
option, interpretation of association findings 
could be supplemented by biological insights 
derived from the laboratory.  
Evaluation of an association in populations 
of different ancestry from that of the initial 
report would generally be expected, because 
genomic variation is greater when compared 
across populations, and should increase con-
fidence in the finding. By contrast, failure to 
replicate in a population different from that of 
the initial report does not necessarily invalidate 
the original finding. In some cases, the differ-
ences in linkage disequilibrium relationships 
across populations can be used to narrow the 
region of interest for later genetic and possible 
functional analysis. Owing to their robustness 
to population stratification, as noted above, 
family-based studies can also serve as valuable 
replication studies for notable findings48. 
Reports of attempts at replication should 
distinguish between tests of the same SNP as 
in the original study, SNPs in strong linkage 
disequilibrium with the reported SNP, and 
other SNPs that were genotyped to search for 
additional variants associated with disease in 
the region (Fig. 1). In some circumstances, the 
initial study might have identified a marker 
that is not in strong linkage disequilibrium with 
the causal variant, which could lead to a false 
refutation in a different population, whereas 
testing additional SNPs in the region might 
reveal another association worthy of follow-
up. For clarity, if new, previously untested SNPs 
are included, they should be clearly identified 
and the rationale for their inclusion explicitly 
stated. If differences in linkage disequilibrium 
patterns across populations are used to invoke 
an association at a new marker but not at the 
originally tested marker, the different linkage 
disequilibrium patterns should be empirically 
demonstrated in the appropriate populations 
and shown to be a plausible and consistent 
explanation for both the new and original 
results. Otherwise, the new association can-
not be considered a replication.
Publication of associations 
The evaluation of a publication addressing one 
or more genotype–phenotype associations 
is a daunting task in the age of large, dense 
datasets. To this end, published genome-wide 
association reports should include detailed 
descriptions of design, genotyping and statisti-
cal methods, and results, even if available only 
through online supplements, or perhaps in a 
separate journal. A checklist of key possible 
issues is provided in Box 1 — this could be 
used as a guide for authors, editors, reviewers 
and the general readership.
It is a challenge to make the case for the 
importance of the replication finding(s) with-
out exaggerating the significance of the obser-
vation. Remarks about possible follow-up of 
genetic markers and corroborative studies to 
investigate plausibility should be brief and well 
referenced. Authors should practise sound 
judgement and temper enthusiasm based on 
prior publications (especially from the same 
investigative group), particularly if the replica-
tion study results differ from those of the initial 
study. Disclosure of known previous attempts 
to replicate the reported findings, whether 
positive or negative, by the authors or others 
is important for interpreting the replication 
study.
Although it is desirable for the initial report 
of a genotype–phenotype association to 
include adequately powered replication stud-
ies, requiring replication with every initial 
study may not be necessary, as long as the pre-
liminary nature of a study without replication 
is emphasized. Such studies can still provide 
valuable information if the entire set of results 
is made available, and releasing such results 
before replication would be of value to the field. 
However, there is substantial added value in 
presenting robust findings based on an initial 
scan together with follow-up replication, and 
an appropriate balance is needed that facilitates 
rapid publication of valid findings and encour-
ages collaboration19,65. If replication studies are 
included, each should be described or refer-
enced in the same detail as the initial study and 
should include the results for all SNPs tested at 
each stage.  As noted above, replication studies 
should preferably investigate the same or a very 
similar phenotype. 
In many cases, the follow-up study will fail 
to replicate the initial results. Such findings 
are valuable for distinguishing false-positives 
from the true-positive signals that should be 
pursued for putative causal variants. The pref-
erence for publishing positive findings, even 
if derived from suboptimal studies, presents 
a formidable barrier to the dissemination of 
well-conducted negative studies. Failure to dis-
seminate results from well-conducted negative 
studies withholds essential pieces of evidence 
for investigators who may be deciding whether 
to launch a follow-up study to replicate or to 
extend the original study. Thus, high-quality 
instances of ‘meaningful negativity’ are use-
ful and should be reported succinctly in the 
literature. Criteria for a meaningful negative 
These criteria are intended for follow-up 
studies of initial reports of genotype–
phenotype associations assessed by genome-
wide or candidate-gene approaches. 
• Replication studies should be of sufficient 
sample size to convincingly distinguish the 
proposed effect from no effect 
• Replication studies should preferably be 
conducted in independent data sets, to avoid 
the tendency to split one well-powered study 
into two less conclusive ones 
• The same or a very similar phenotype should 
be analysed
• A similar population should be studied, 
and notable differences between the 
populations studied in the initial and 
attempted replication studies should be 
described
• Similar magnitude of effect and significance 
should be demonstrated, in the same 
direction, with the same SNP or a SNP in 
perfect or very high linkage disequilibrium 
with the prior SNP (r2 close to 1.0) 
• Statistical significance should first be 
obtained using the genetic model reported in 
the initial study 
• When possible, a joint or combined analysis 
should lead to a smaller P-value than that 
seen in the initial report75 
• A strong rationale should be provided for 
selecting SNPs to be replicated from the 
initial study, including linkage-disequilibrium 
structure, putative functional data or 
published literature
• Replication reports should include the same 
level of detail for study design and analysis 
plan as reported for the initial study (Box 1)










Figure 1 | Linkage disequilbrium across the region containing SNPs associated with breast cancer 
in FGFR2. Black diamonds represent four single nucleotide polymorphisms (SNPs; rs11200014, 
rs2981579, rs1219648 and rs2420946) for which associations with breast cancer were replicated in 
multiple studies73,74. Estimates of the square of the correlation coefficient (r2) were calculated for each 
pairwise comparison of SNPs in the initial genome-wide association study across the FGFR2 region73. 
The log(10) r2 values are colour-coded.
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replication study are the same as those for a 
positive study (Box 3), with the added require-
ments that the same trait should be studied in a 
population of comparable underlying structure 
with sufficient power to measure the appropri-
ate effect size and yield a negative result.
Negative studies are difficult to publish 
but they are crucial for separating true-posi-
tive from false-positive findings. Journals are 
strongly encouraged to publish high-qual-
ity negative studies refuting earlier positive 
reports of genotype–phenotype associations. 
The journal in which the initial scan is pub-
lished is encouraged to solicit and publish 
well-conducted follow-up studies within a 
specified time frame, perhaps between 3 and 
9 months of the initial report. A case in point 
is the recent collection of reports published by 
The American Journal of Human Genetics66–71 
that failed to replicate the initial findings of a 
genome-wide association study on Parkinson’s 
disease. A handful of journals — such as Can-
cer Epidemiology, Biomarkers and Prevention 
and the new PLoS series72 — currently feature 
well-conducted negative reports, and such 
efforts are to be lauded. The value of a well-
executed negative study cannot be overempha-
sized; more venues are needed to capture these 
valuable results.
Although there are challenges to making data 
on individual research participants available to 
other investigators, every effort should be made 
to provide researchers with an opportunity to 
reproduce the reported results and to investi-
gate new hypotheses and methods. To facilitate 
this research in genome-wide association stud-
ies, a public data archive known as the Data-
base of Genotypes and Phenotypes, or dbGaP 
(http://view.ncbi.nlm.nih.gov/dbgap) has been 
established at the National Library of Medicine’s 
National Center for Biotechnology Information 
and will be used by many National Institutes 
of Health (NIH)-supported studies. dbGaP 
will provide study documentation and aggre-
gated genotype and phenotype data through 
its website with no account or authorization 
required. Access to individual, de-identified 
genotype and phenotype data will require an 
authorization and approval process that is cur-
rently under development. Whether through 
dbGaP or other venues, genotype summaries of 
computed analyses should be published online 
unless there are strong reasons not to do so, such 
as data derived from special populations (that 
is, isolated populations or minority communi-
ties) or other groups that will not permit such 
sharing. There are substantial informatic chal-
lenges for data presentation and data archiving, 
especially on public and journal websites. Best 
practices for retrieval and analysis of such data 
continue to evolve.
Conclusion
The history of genotype–phenotype associa-
tion studies has focused on initial discoveries 
as opposed to careful replication. Earlier atten-
tion to the appropriate design of subsequent 
replication studies might have helped limit the 
plethora of false-positive results. Determina-
tion of valid genotype–phenotype associations 
presents a series of challenges that will require 
a logical strategy for conducting well-designed 
studies, based on excellent quality control 
practices interwoven with sound analytical 
methods and judicious interpretation. Other 
than the obvious differences in the drawbacks 
involved in multiple comparisons, standards 
for assessing the validity of the initial findings 
of a genotype–phenotype association should 
not differ substantially between the candidate-
gene approach and genome-wide association 
studies. As experience accumulates, we can 
look forward to methodological advances 
that will facilitate our interpretation of stud-
ies, such as continued improvement of pro-
posed methods for lowering the threshold for 
positive findings, adjustments for population 
structure, and exploitation of linkage disequi-
librium structure in a candidate region.
The best practices suggested here for report-
ing initial and replication studies are based on 
sufficient disclosure of study methods to permit 
independent confirmation of study findings. 
Often a sequence of studies will be required 
to establish a valid genotype–phenotype asso-
ciation, perhaps involving several rounds of 
replication studies. And, of course, the conclu-
sive demonstration of a replicated association 
represents only the beginning of the process 
towards finding the causal genetic variant(s). 
Labour-intensive and costly investigation will 
subsequently be required to sequence the can-
didate interval in depth, genotype all the com-
mon and perhaps uncommon variants that are 
markers for the outcomes of interest in multiple 
population samples, understand their func-
tional consequences, examine their potential 
interactions with other genes or environmental 
factors, and devise strategies for preventative or 
therapeutic interventions.  None of these steps 
should proceed far, however, without conclu-
sive replication of findings from an initial geno-
type–phenotype association study. ■
Note added in proof: Recently, a series of papers 
have also shown replication across as well as 
within genome-wide association studies in 
common complex diseases such as breast 
cancer, type 2 diabetes, and coronary dis-
ease73,74,76–81.
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